Antitumor activity and mechanism of resistance of the novel HDAC and PI3K dual inhibitor CUDC-907 in pancreatic cancer

被引：0
|
作者：
Shuang Liu
Shoujing Zhao
Yang Dong
Tingting Wang
Xiaojia Niu
Lijing Zhao
Guan Wang
机构：
[1] Jilin University,Key Laboratory for Molecular Enzymology and Engineering, National Engineering Laboratory for AIDS Vaccine, The Ministry of Education, School of Life Sciences
[2] Jilin University,Department of Rehabilitation, School of Nursing
来源：
Cancer Chemotherapy and Pharmacology | 2021年 / 87卷
关键词：
CUDC-907; Antitumor activity; Combination treatment; VS-5584; Pancreatic cancer;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
页码：415 / 423
页数：8
相关论文
共 50 条
  • [1] Antitumor activity and mechanism of resistance of the novel HDAC and PI3K dual inhibitor CUDC-907 in pancreatic cancer
    Liu, Shuang
    Zhao, Shoujing
    Dong, Yang
    Wang, Tingting
    Niu, Xiaojia
    Zhao, Lijing
    Wang, Guan
    CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2021, 87 (03) : 415 - 423
  • [2] Antitumor activity of CUDC-907, a dual PI3K and HDAC inhibitor, in hematological cancer models
    Rudi, Bao
    Wang, Dagong
    Qu, Hui
    Yin, Ling
    Zifcak, Brian
    DellaRocca, Steven
    Xu, Guang-Xin
    Borek, Mylissa
    Samson, Maria
    Atoyan, Ruzanna
    Poll, Anne
    Wang, Jing
    Zhai, Hai-Xaio
    Lai, Cheng-Jung
    Pepicelli, Carmen
    Cai, Xiong
    Qian, Changgeng
    CANCER RESEARCH, 2012, 72
  • [3] CUDC-907, a novel dual PI3K and HDAC inhibitor, in prostate cancer: Antitumour activity and molecular mechanism of action
    Hu, Cheng
    Xia, Hongyan
    Bai, Shanshan
    Zhao, Jianlei
    Edwards, Holly
    Li, Xinyu
    Yang, Yanrong
    Lyu, Jing
    Wang, Guan
    Zhan, Yang
    Dong, Yan
    Ge, Yubin
    JOURNAL OF CELLULAR AND MOLECULAR MEDICINE, 2020, 24 (13) : 7239 - 7253
  • [4] CUDC-907, a dual HDAC and PI3K inhibitor, reverses platinum drug resistance
    To, Kenneth K. W.
    Fu, Li-wu
    INVESTIGATIONAL NEW DRUGS, 2018, 36 (01) : 10 - 19
  • [5] CUDC-907, a dual HDAC and PI3K inhibitor, reverses platinum drug resistance
    Kenneth K. W. To
    Li-wu Fu
    Investigational New Drugs, 2018, 36 : 10 - 19
  • [6] Characterization of the HDAC/PI3K inhibitor CUDC-907 as a novel senolytic
    Al-Mansour, Fares
    Alraddadi, Abdullah
    He, Buwei
    Saleh, Anes
    Poblocka, Marta
    Alzahrani, Wael
    Cowley, Shaun
    Macip, Salvador
    AGING-US, 2023, 15 (07): : 2373 - 2394
  • [7] CUDC-907, a new dual PI3K and HDAC inhibitor, as ATL therapeutics
    Mori, Naoki
    Ishikawa, Chie
    CANCER SCIENCE, 2018, 109 : 294 - 294
  • [8] Novel dual HDAC & PI3K inhibitor, CUDC-907, for MYC-driven malignancies
    Sun, Kaiming
    Atoyan, Ruzanna
    Borek, Mylissa A.
    Dellarocca, Steven
    Samson, Maria E.
    Ma, Anna W.
    Xu, Guangxin
    Patterson, Troy
    Tuck, David P.
    Viner, Jaye L.
    Fattaey, Ali
    Wang, Jing
    CANCER RESEARCH, 2016, 76
  • [9] CUDC-907, a Dual HDAC and PI3K Inhibitor, Potentially Targets Cancer Cells and The Microenvironment In Hematological Malignancies
    Wang, Jing
    Pursell, Natalie
    Ma, Anna
    Atoyan, Ruzanna
    Samson, Maria
    Borek, Mylissa
    DellaRocca, Steven
    Yin, Ling
    Wang, Da-gong
    Zifcak, Brian
    Xu, Guang-xin
    Voi, Maurizio
    Lai, Cheng-Jung
    BLOOD, 2013, 122 (21)
  • [10] CUDC-907: An Oral HDAC/PI3K Dual Inhibitor with Strong Preclinical Efficacy in MCL Model
    Boyle, Jordan N.
    Kim, Caroline R.
    Guo, Hui
    Bell, Taylor
    Huang, Shengjian
    Li, Carrie J.
    Liu, Yang
    Zhang, Hui
    Wang, Jack
    Zhang, Victoria
    Ahmed, Makhdum
    Lam, Laura T.
    Nomie, Krystle
    Zhang, Liang
    Zeng, Dongfeng
    Wang, Michael
    BLOOD, 2016, 128 (22)
12345